Ercros, S.A.
Spain · ES0125140A14 · reports in EUR · Europe
Four figures
From the annual report for the year to Dec 31, 2025. Each line says what it is based on.
- Revenue growth
- Revenue −5.4% in the year to Dec 31, 2025, on the year before.
- Return on equity
- It earned −19% on its shareholders' equity in the year to Dec 31, 2025.
- Equity and assets
- Equity is 41% of its assets, and operations brought in cash in the year.
- Price and earnings
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2025, consolidated, in EUR.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | |
|---|---|---|---|---|
| Revenue | n/a | €758M | €700M | €663M |
| Operating profit | €92M | €13M | −€3M | −€28M |
| Earnings per share | €0.64 | €0.29 | −€0.13 | −€0.59 |
| Dividend per share | n/a | n/a | n/a | €0.10 |
| Cash from operations | n/a | €55M | €10M | €49M |
| Capital spending | €27M | n/a | n/a | n/a |
| Cash | €58M | €39M | €37M | €96M |
| Total assets | €747M | €683M | €699M | €694M |
| Equity | €361M | €363M | €341M | €287M |
What they do
In the company's own words, from the annual report.
la producción y comercialización de productos químicos y principios activos farmacéuticos genéricos La actividad del Grupo se desarrolla a través de tres segmentos de negocios [ver el apartado 1.3 d) del informe de gestión consolidado («IGC») y la nota 3 e) de las cuentas anuales consolidadas]: - La división de derivados del cloro (cloro, sosa cáustica, hipoclorito sódico, ácido clorhídrico, ATCC, PVC, oxidantes y otros productos). - La división de química intermedia (formaldehído y derivados). - La división de farmacia que produce principios activos farmacéuticos genéricos (eritromicinas, ácido fusídico y fosfomicinas, principalmente).
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the ratios from the filed figures.